1887

Journal of General Virology

Volume 98, Issue 4

Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library Free

Abstract

With the recent development of single B-cell cloning techniques, an increasing number of human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing antibodies have been isolated since 2009. However, knowledge regarding HIV-1-specific B cells is limited. In this study, an HIV-1-specific B-cell line was established using healthy PBMC donors by the highly efficient Epstein–Barr virus transformation method to generate immortalized human naïve B-cell libraries. The enrichment of HIV-1 envelope-specific B cells was observed after four rounds of cell panning with the HIV-1 envelope glycoprotein. An HIV-1 envelope-specific stable B-cell line (LCL-P4) was generated. Although this cell line acquired a lymphoblastic phenotype, no expression was observed for activation-induced cytidine deaminase, an enzyme responsible for initiating somatic hypermutation and class switch recombination in B cells. This study describes a method that enables fast isolation of HIV-1-specific B cells, and this approach may extend to isolating other B-cell-specific antigens for further experiments.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): AID , antibodies , cell sorting , HIV-1-specific B cells , neutralization and stable B cell line
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000706
2017-04-01
2020-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/4/791.html?itemId=/content/journal/jgv/10.1099/jgv.0.000706&mimeType=html&fmt=ahah

References

  1. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011;7:e1001251 [CrossRef][PubMed]
     [Google Scholar]
  2. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P et al. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 2009;326:285–289 [CrossRef][PubMed]
     [Google Scholar]
  3. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:856–861 [CrossRef][PubMed]
     [Google Scholar]
  4. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014;158:989–999 [CrossRef][PubMed]
     [Google Scholar]
  5. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012;492:118–122 [CrossRef][PubMed]
     [Google Scholar]
  6. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016;375:2037–2050 [CrossRef][PubMed]
     [Google Scholar]
  7. West AP, Scharf L, Scheid JF, Klein F, Bjorkman PJ et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014;156:633–648 [CrossRef][PubMed]
     [Google Scholar]
  8. Hilleman MR. Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology 2002;45:199–211 [CrossRef][PubMed]
     [Google Scholar]
  9. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055–1065 [CrossRef][PubMed]
     [Google Scholar]
  10. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012;37:412–425 [CrossRef][PubMed]
     [Google Scholar]
  11. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010;467:591–595 [CrossRef][PubMed]
     [Google Scholar]
  12. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012;30:423–433 [CrossRef][PubMed]
     [Google Scholar]
  13. Hoot S, Mcguire AT, Cohen KW, Strong RK, Hangartner L et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013;9:e1003106[Crossref]
     [Google Scholar]
  14. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013;340:711–716 [CrossRef][PubMed]
     [Google Scholar]
  15. Yang Z, Li J, Liu Q, Yuan T, Zhang Y et al. Identification of non-HIV immunogens that bind to germline b12 predecessors and prime for elicitation of cross-clade neutralizing HIV-1 antibodies. PLoS One 2015;10:e0126428 [CrossRef][PubMed]
     [Google Scholar]
  16. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011;331:1203–1207 [CrossRef][PubMed]
     [Google Scholar]
  17. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871–875 [CrossRef][PubMed]
     [Google Scholar]
  18. Rosén A, Gergely P, Jondal M, Klein G, Britton S. Polyclonal Ig production after Epstein–Barr virus infection of human lymphocytes in vitro. Nature 1977;267:52–54 [CrossRef][PubMed]
     [Google Scholar]
  19. Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997;156:111–126 [CrossRef][PubMed]
     [Google Scholar]
  20. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553–563 [CrossRef][PubMed]
     [Google Scholar]
  21. Yu X, Tsibane T, Mcgraw PA, House FS, Keefer CJ et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008;455:532–536 [CrossRef][PubMed]
     [Google Scholar]
  22. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010;5:e8805 [CrossRef][PubMed]
     [Google Scholar]
  23. Yuan T, Li J, Zhang MY. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. MAbs 2011;3:402–407 [CrossRef][PubMed]
     [Google Scholar]
  24. Sun Z, Li J, Hu X, Shao Y, Zhang MY. Reconstitution and characterization of antibody repertoires of HIV-1-infected “elite neutralizers”. Antiviral Res 2015;118:1–9 [CrossRef][PubMed]
     [Google Scholar]
  25. Dorner M, Zucol F, Berger C, Byland R, Melroe GT et al. Distinct ex vivo susceptibility of B-cell subsets to epstein–barr virus infection according to differentiation status and tissue origin. J Virol 2008;82:4400–4412 [CrossRef][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000706
Loading
Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library
J. Gen. Virol. 98, 791 (2017); https://doi.org/10.1099/jgv.0.000706
/content/journal/jgv/10.1099/jgv.0.000706
/content/journal/jgv/10.1099/jgv.0.000706
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error